NewEdge Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

NewEdge Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-412	Closed	-$36	–	3930
2023 Q3	$36	Buy	+412	New	+$38	﹤0.01%	3409

Other funds holding NAVB

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

NewEdge Advisors's NAVB Position: Q4 2023 in Review

NewEdge Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2023, closing a stake of 412 shares — an estimated $36 sold.

NewEdge Advisors first reported a position in NAVB in Q3 2023 and held it in 1 quarter. The position peaked at $36 in Q3 2023. 4 funds tracked by Wall St. Rank hold NAVB as of Q4 2023.

NewEdge Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2023 after selling out during the quarter.
NewEdge Advisors sold 412 Navidea Biopharmaceuticals Inc. shares in Q4 2023, an estimated $36.
NewEdge Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2023 and held it in 1 quarter.
NewEdge Advisors's Navidea Biopharmaceuticals Inc. position peaked at $36 in Q3 2023.
4 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2023.

Based on NewEdge Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.